David Margolin

5.6k total citations · 2 hit papers
125 papers, 4.0k citations indexed

About

David Margolin is a scholar working on Pathology and Forensic Medicine, Rheumatology and Immunology. According to data from OpenAlex, David Margolin has authored 125 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Pathology and Forensic Medicine, 31 papers in Rheumatology and 29 papers in Immunology. Recurrent topics in David Margolin's work include Multiple Sclerosis Research Studies (69 papers), Rheumatoid Arthritis Research and Therapies (20 papers) and Polyomavirus and related diseases (15 papers). David Margolin is often cited by papers focused on Multiple Sclerosis Research Studies (69 papers), Rheumatoid Arthritis Research and Therapies (20 papers) and Polyomavirus and related diseases (15 papers). David Margolin collaborates with scholars based in United States, United Kingdom and Germany. David Margolin's co-authors include Alasdair Coles, Krzysztof Selmaj, Edward Fox, D. A. S. Compston, Eva Havrdová, Douglas L. Arnold, Stephen Lake, Jeffrey Cohen, Michael Panzara and Howard L. Weiner and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and The Journal of Experimental Medicine.

In The Last Decade

David Margolin

121 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

2012 884 citations Alasdair Coles, Cary Twyman et al. profile →
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

2012 883 citations Jeffrey Cohen, Alasdair Coles et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Margolin United States	26	2.8k	1.2k	1.1k	1.1k	831	125	4.0k
Daniel Wynn United States	26	2.7k 1.0×	1.0k 0.9×	792 0.7×	1.1k 1.1×	653 0.8×	50	3.6k
Frances Lynn United States	13	3.6k 1.3×	1.9k 1.6×	1.1k 1.0×	1.2k 1.1×	760 0.9×	19	4.7k
Anders Svenningsson Sweden	38	3.4k 1.2×	1.1k 1.0×	1.2k 1.1×	1.7k 1.6×	620 0.7×	110	5.4k
Jeffrey Cohen United States	16	2.4k 0.9×	776 0.7×	701 0.6×	924 0.9×	709 0.9×	52	3.0k
John R. Corboy United States	32	2.3k 0.8×	527 0.4×	730 0.6×	1.1k 1.1×	628 0.8×	110	3.9k
Katherine Miszkiel United Kingdom	29	3.0k 1.1×	940 0.8×	665 0.6×	1.3k 1.2×	945 1.1×	47	4.4k
Lucia Moiola Italy	40	3.6k 1.3×	789 0.7×	658 0.6×	1.8k 1.7×	811 1.0×	160	4.9k
J. S. Wolinsky United States	19	2.8k 1.0×	600 0.5×	755 0.7×	1.4k 1.3×	922 1.1×	38	3.4k
Vesna Brinar Croatia	22	2.6k 0.9×	600 0.5×	576 0.5×	1.2k 1.1×	781 0.9×	99	3.5k
Neil P. Robertson United Kingdom	38	2.9k 1.0×	537 0.5×	1.2k 1.0×	1.6k 1.5×	822 1.0×	151	4.9k

Countries citing papers authored by David Margolin

Since Specialization

Citations

This map shows the geographic impact of David Margolin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Margolin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Margolin more than expected).

Fields of papers citing papers by David Margolin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Margolin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Margolin. The network helps show where David Margolin may publish in the future.

Co-authorship network of co-authors of David Margolin

This figure shows the co-authorship network connecting the top 25 collaborators of David Margolin. A scholar is included among the top collaborators of David Margolin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Margolin. David Margolin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Wijmeersch, Bart Van, B. Singer, Aaron Boster, et al.. (2019). Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies. Multiple Sclerosis Journal. 26(13). 1719–1728. 16 indexed citations

2.

Oreja‐Guevara, Celia, Raed Alroughani, David Brassat, et al.. (2017). Alemtuzumab demonstrated durable efficacy and safety in CARE-MS I patients switching from SC IFNB-1a: 5-year follow-up after alemtuzumab (TOPAZ study). Queensland's institutional digital repository (The University of Queensland). 1 indexed citations

3.

Arnold, Douglas L., Michael Barnett, Cristoforo Comi, et al.. (2017). Durable Reduction in MRI Disease Activity With Alemtuzumab in the Absence of Continuous Treatment in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Were Treatment-Naive: 6-Year Follow-up of the CARE-MS I Study (S10.002). Neurology. 88(16_supplement).

4.

Fox, Edward, David Brassat, Raed Alroughani, et al.. (2017). Alemtuzumab Provides Durable Efficacy Over 6 Years in Patients With Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy in the Absence of Continuous Treatment (CARE-MS II) (S24.006). Neurology. 88(16_supplement). 2 indexed citations

5.

Rovira, Àlex, Aaron Boster, Giancarlo Comi, et al.. (2017). Alemtuzumab Decreased MRI Disease Activity Through 6 Years in Patients With Highly Active RRMS and an Inadequate Response to Prior Therapy: CARE-MS II Extension Study (S12.006). Neurology. 88(16_supplement). 1 indexed citations

6.

McCombe, Pamela, HP Hartung, Eva Havrdová, et al.. (2016). Durable Effect of Alemtuzumab on Clinical Outcomes Over 5 years in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Despite Most Patients Not Receiving Treatment for 4 Years: CARE-MS I Extension Study. Multiple Sclerosis Journal. 22(3). 406–407. 2 indexed citations

7.

Coles, Alasdair, Alexey Boyко, J. A. Cohen, et al.. (2016). Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).. Multiple Sclerosis Journal. 22. 75–76. 7 indexed citations

8.

LaGanke, Christopher, J. de Sèze, M. S. Freedman, et al.. (2016). Durable suppression of disease activity by alemtuzumab in the absence of continuous treatment over 6 years in patients with active relapsing-remitting multiple sclerosis and an inadequate response to prior therapy (CARE-MS II). Multiple Sclerosis Journal. 22(2). 327–328. 1 indexed citations

9.

Schippling, Sven, Jeffrey A. Cohen, Alasdair Coles, et al.. (2016). Alemtuzumab-Treated Patients with RRMS Demonstrate Durable Slowing of Brain Volume Loss Over 5 Years Despite Most Being Treatment-Free for 4 Years: CARE-MS I and II Extension Study (S51.001). Neurology. 86(16_supplement). 2 indexed citations

10.

Singer, B., Stephen Krieger, Regina Berkovich, et al.. (2016). Patients Who Had Highly Active RRMS and an Inadequate Response to Prior Therapy Demonstrated Durable Efficacy with Alemtuzumab: 5-Year Follow-Up of the CARE-MS II Study (P6.164). Neurology. 86(16_supplement). 5 indexed citations

11.

Krieger, Stephen, B. Singer, Mark S. Freedman, et al.. (2016). Treatment-Naive Patients with Highly Active RRMS Demonstrated Durable Efficacy with Alemtuzumab over 5 Years (S51.003). Neurology. 86(16_supplement). 7 indexed citations

12.

Singer, B., Edward Fox, Stephen Krieger, et al.. (2015). Durable Efficacy of Alemtuzumab in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis Who Relapsed on a Prior Therapy (P7.269). Neurology. 84(14_supplement). 1 indexed citations

13.

Achiron, Anat, Christina Chambers, P Combe, et al.. (2015). Pregnancy outcomes in patients with active RRMS who received alemtuzumab in the clinical development program. Multiple Sclerosis Journal. 21. 581–582. 9 indexed citations

14.

Graves, Jennifer, Laura J. Balcer, Jeffrey Palmer, David Margolin, & Steven Galetta. (2014). Alemtuzumab Improves Visual Outcomes vs. Subcutaneous Interferon Beta-1a in Patients With Active Relapsing-Remitting Multiple Sclerosis (RRMS) Who Relapsed on Prior Therapy: Analysis From the CARE-MS II Study (I7-1.010). Neurology. 82(10_supplement). 2 indexed citations

15.

Graves, Jennifer, Laura J. Balcer, Jeffrey Palmer, David Margolin, & Steven Galetta. (2014). Alemtuzumab Improves Visual Outcomes vs. Subcutaneous Interferon Beta-1a in Patients With Active Relapsing-Remitting Multiple Sclerosis (RRMS) Who Relapsed on Prior Therapy: Analysis From the CARE-MS II Study (P3.158). Neurology. 82(10_supplement).

16.

Hartung, Hans, Timothy Vollmer, Douglas L. Arnold, et al.. (2013). Alemtuzumab Reduces MS Disease Activity in Active Relapsing-Remitting Multiple Sclerosis Patients Who Had Disease Activity on Prior Therapy (P07.093). Neurology. 80(7_supplement). 2 indexed citations

17.

Sørensen, Per Soelberg, Douglas L. Arnold, Jeffrey A. Cohen, et al.. (2013). Immunogenicity of Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients in the CARE-MS II Study (P07.101). Neurology. 80(7_supplement). 4 indexed citations

18.

Giovannoni, Gavin, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Disability Improvement with Alemtuzumab vs. Interferon beta-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P07.120). Neurology. 80(7_supplement). 1 indexed citations

19.

Daniels, Gilbert H., Anton Vladić, Vesna Brinar, et al.. (2013). Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis. The Journal of Clinical Endocrinology & Metabolism. 99(1). 80–89. 111 indexed citations

20.

Wray, Sibyl, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Comparison of Infection Risk with Alemtuzumab and SC IFNB-1a in Patients with Multiple Sclerosis Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P01.172). Neurology. 80(7_supplement). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact